These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 26729879)

  • 1. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
    Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.
    Montoya M; Gresh L; Mercado JC; Williams KL; Vargas MJ; Gutierrez G; Kuan G; Gordon A; Balmaseda A; Harris E
    PLoS Negl Trop Dis; 2013; 7(8):e2357. PubMed ID: 23951377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.
    Clapham HE; Rodriguez-Barraquer I; Azman AS; Althouse BM; Salje H; Gibbons RV; Rothman AL; Jarman RG; Nisalak A; Thaisomboonsuk B; Kalayanarooj S; Nimmannitya S; Vaughn DW; Green S; Yoon IK; Cummings DA
    J Infect Dis; 2016 May; 213(9):1428-35. PubMed ID: 26704615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the human serum antibody response to secondary dengue virus infections.
    Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
    Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
    J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).
    Azami NAM; Moi ML; Ami Y; Suzaki Y; Lim CK; Taniguchi S; Saijo M; Takasaki T; Kurane I
    Virol J; 2018 Mar; 15(1):51. PubMed ID: 29587780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.
    Ly MHP; Moi ML; Vu TBH; Tun MMN; Saunders T; Nguyen CN; Nguyen AKT; Nguyen HM; Dao TH; Pham DQ; Nguyen TTT; Le TQM; Hasebe F; Morita K
    BMC Infect Dis; 2018 Jan; 18(1):31. PubMed ID: 29321001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.
    Ito M; Katakai Y; Ono F; Akari H; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2011 Jun; 156(6):1073-7. PubMed ID: 21409446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.
    Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S
    J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.
    Henein S; Adams C; Bonaparte M; Moser JM; Munteanu A; Baric R; de Silva AM
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34003796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.
    Puschnik A; Lau L; Cromwell EA; Balmaseda A; Zompi S; Harris E
    PLoS Negl Trop Dis; 2013; 7(6):e2274. PubMed ID: 23785536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
    Messer WB; de Alwis R; Yount BL; Royal SR; Huynh JP; Smith SA; Crowe JE; Doranz BJ; Kahle KM; Pfaff JM; White LJ; Sariol CA; de Silva AM; Baric RS
    Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1939-44. PubMed ID: 24385585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru.
    Forshey BM; Reiner RC; Olkowski S; Morrison AC; Espinoza A; Long KC; Vilcarromero S; Casanova W; Wearing HJ; Halsey ES; Kochel TJ; Scott TW; Stoddard ST
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004398. PubMed ID: 26848841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
    Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
    Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
    de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
    BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.
    Buddhari D; Aldstadt J; Endy TP; Srikiatkhachorn A; Thaisomboonsuk B; Klungthong C; Nisalak A; Khuntirat B; Jarman RG; Fernandez S; Thomas SJ; Scott TW; Rothman AL; Yoon IK
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3230. PubMed ID: 25329173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].
    Hu D; Li J; Wang D; DI B; Qiu L; Wang Y; Ding X; Che X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1773-6, 1791. PubMed ID: 23268408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.